Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) Net Income towards Common Stockholders: 2019-2025

Historic Net Income towards Common Stockholders for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -$86.4 million.

  • Nurix Therapeutics' Net Income towards Common Stockholders fell 76.53% to -$86.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$244.8 million, marking a year-over-year decrease of 38.32%. This contributed to the annual value of -$193.6 million for FY2024, which is 34.47% down from last year.
  • Nurix Therapeutics' Net Income towards Common Stockholders amounted to -$86.4 million in Q3 2025, which was down 98.83% from -$43.5 million recorded in Q2 2025.
  • Nurix Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$24.3 million during Q1 2021, with a 5-year trough of -$86.4 million in Q3 2025.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$43.5 million (2025), whereas its average is -$47.6 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Net Income towards Common Stockholders crashed by 448.05% in 2021, and later soared by 46.53% in 2023.
  • Nurix Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$37.7 million in 2021, then decreased by 23.95% to -$46.7 million in 2022, then grew by 10.19% to -$42.0 million in 2023, then plummeted by 39.55% to -$58.5 million in 2024, then plummeted by 76.53% to -$86.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$86.4 million for Q3 2025, versus -$43.5 million for Q2 2025 and -$56.4 million for Q1 2025.